Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

Cancer

Volumn 120, Issue 4, 2014, Pages 603-610

  MacKay, Helen J ^a   Eisenhauer, Elizabeth A ^b   Kamel Reid, Suzanne ^a   Tsao, Ming ^a   Clarke, Blaise ^a   Karakasis, Katherine ^a   Werner, Henrica M J ^c   Trovik, Jone ^c   Akslen, Lars A ^d   Salvesen, Helga B ^c   Tu, Dongsheng ^b   Oza, Amit M ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Queen's Cancer Research Institute   (Canada)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

endometrial cancer; metformin; predictive biomarkers; rapalogs; stathmin

Indexed keywords

ENDOMETRIAL CANCER; METFORMIN; PREDICTIVE BIOMARKERS; RAPALOGS; STATHMIN;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84893764401     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28414     Document Type: Article

References (31)

1. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the ncic clinical trials group. J Clin Oncol. 2011; 29: 3278-3285.
2. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-456.
3. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009; 27: 3822-3829.
4. Ihle NT, Lemos R Jr, Wipf P, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009; 69: 143-150.
5. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008; 14: 1351-1356.
6. Torvik J, Wik E, Stefansson IM, et al. Stathmin over expression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res. 2011; 17: 3368-3377.
7. Emons G, Heyl W,. Hormonal treatment of endometrial cancer. J Cancer Res Clin Oncol. 2000; 126: 619-623.
8. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999; 17: 1736-1744. (Pubitemid 29269242)
9. Swenerton KD, White GW, Boyes DA,. Treatment of advanced endometrial carcinoma with tamoxifen. N Engl J Med. 1979; 301: 105. (Pubitemid 9229704)
10. Bellone S, Shah HR, McKenney JK, et al. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol. 2008; 199: e7-e10.
11. Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004; 14: 650-658. (Pubitemid 39062922)
12. Deppe G, Malviya VK, Malone JM, Christensen CW, Saunders D,. Treatment of recurrent and metastatic endometrial cancer with cisplatin and doxorubicin. Eur J Gynaecol Oncol. 1994; 15: 263-266. (Pubitemid 24247942)
13. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004; 22: 2159-2166. (Pubitemid 41095150)
14. Salvesen HB, Stefansson I, Kretzschmar EI, et al. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol. 2004; 25: 1615-1623.
15. Mackay HJ, Gallinger S, Tsao M, et al. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC-CTG). Eur J Cancer. 2010; 46: 1365-1373.
16. Lu KH, Wu W, Dave B, et al. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res. 2008; 14: 2543-2550.
17. Hayes MP, Wang H, Espinal-Witter R, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res. 2006; 12: 5932-5935. (Pubitemid 44703751)
18. Janju P, Wheler JJ, Westeni S, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012; 30: 777-782.
19. Mackay H, Welch S, Tsao MS, et al. Phase II trial of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND192 [Abstract]. J Clin Oncol. 2011; 29 (suppl 15): abstract 5013.
20. Dowling RJO, Niraula S, Stambolic V, Goodwin P,. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012; 48: R31-R43.
21. Andersen SS,. Spindle assembly and the art of regulating microtubule dynamics by MAPs and Stathmin/Op18. Trends Cell Biol. 2000; 10: 261-267. (Pubitemid 30387030)
22. Marklund U, Larsson N, Gradin HM, Brattsand G, Gullberg M,. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics EMBO J. 1996; 15: 5290-5298. (Pubitemid 26336212)
23. Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009; 106: 4834-4839.
24. McConechy MK, Ding J, Cheang MCU, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012; 228: 20-30.
25. Oda K, Stokoe D, Taketani Y, et al. High frequency of co-existing mutations of PIK3CA and PTEN genes in endometrial cancer Cancer Res. 2005; 65: 10669-10673. (Pubitemid 41713332)
26. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002; 8: 128-135. (Pubitemid 34155123)
27. Vandenput I, Trovik J, Leunen K, et al. Evolution in endometrial cancer: evidence from an immunohistochemical study. Int J Gynecol Cancer. 2011; 21: 316-322.
28. McAlpine JN, Bashashati A, Ha G, et al. Intratumoral heterogeneity in high-grade serous cancers: defining evolution of the somatic mutational landscape across spatially and temporally selected samples. Proceedings of the 14th Biennial Meeting of the International Gynecologic Cancer Society, Vancouver, Canada; October 13-16, 2012; p E73.
29. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-1417.
30. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
31. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792. (Pubitemid 32222155)